- Home
- CXE vs VERU Comparison
CXE vs VERU Comparison
Compare CXE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXE
- VERU
- Stock Information
- Founded
- CXE 1989
- VERU 1971
- Country
- CXE United States
- VERU United States
- Employees
- CXE N/A
- VERU N/A
- Industry
- CXE Investment Managers
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- CXE Finance
- VERU Health Care
- Exchange
- CXE Nasdaq
- VERU Nasdaq
- Market Cap
- CXE 122.3M
- VERU 107.2M
- IPO Year
- CXE N/A
- VERU 1990
- Fundamental
- Price
- CXE $3.65
- VERU $0.65
- Analyst Decision
- CXE
- VERU Strong Buy
- Analyst Count
- CXE 0
- VERU 4
- Target Price
- CXE N/A
- VERU $4.00
- AVG Volume (30 Days)
- CXE 62.9K
- VERU 1.1M
- Earning Date
- CXE 01-01-0001
- VERU 02-06-2025
- Dividend Yield
- CXE 4.36%
- VERU N/A
- EPS Growth
- CXE N/A
- VERU N/A
- EPS
- CXE 0.07
- VERU N/A
- Revenue
- CXE N/A
- VERU $16,886,419.00
- Revenue This Year
- CXE N/A
- VERU N/A
- Revenue Next Year
- CXE N/A
- VERU N/A
- P/E Ratio
- CXE $51.00
- VERU N/A
- Revenue Growth
- CXE N/A
- VERU 3.62
- 52 Week Low
- CXE $2.95
- VERU $0.36
- 52 Week High
- CXE $3.67
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- CXE 25.18
- VERU 42.01
- Support Level
- CXE $3.63
- VERU $0.60
- Resistance Level
- CXE $3.91
- VERU $0.82
- Average True Range (ATR)
- CXE 0.05
- VERU 0.07
- MACD
- CXE -0.02
- VERU -0.01
- Stochastic Oscillator
- CXE 7.14
- VERU 22.32
About CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.